A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

Emerging technologies help researchers draw mechanistic links between metabolism and epigenetic modification of DNA.

The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 

The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.

A small clinical trial demonstrates that peptide immunotherapy can halt the progression of early-stage type 1 diabetes.

Researchers continue to identify new T-cell subtypes—and devise ways to use them to fight cancer. The Scientist attempts to catalog them all.

Overzealous activity by mucosa-associated invariant T (MAIT) cells in response to bacterial toxins can lead to illness instead of stopping it.

A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes. 

Identifying immune cell subsets with CyTOF